candycrushgamecandycrushgame| Nuocheng Jianhua is now up by more than 3% and patients have been enrolled in the ICP-488 Phase II clinical trial for psoriasis

Northrift Jianhua (09969) rose 3.3 percent in early tradingcandycrushgamecandycrushgame.41%candycrushgamecandycrushgame, currently quoted at HK$5.16, with a turnover of HK$11.9804 million.

On May 16, Nuocheng Jianhua announced that it had completed the enrollment of patients in the phase II clinical trial of ICP-488, the company's independently developed TYK2 (tyrosine kinase 2) JH2 allosteric inhibitor for the treatment of psoriasis. ICP-488 has demonstrated good effectiveness and safety in a Phase 1 study in the treatment of psoriasis patients.